Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Thera (NQ: AXSM )

69.01 +0.80 (+1.17%)
Streaming Delayed Price Updated: 3:30 PM EDT, Apr 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Axsome Thera

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Billionaires Are Buying These 2 Ultra-High Yield Dividend Stocks Hand Over Fist. Are They Smart Buys for Your Portfolio?
Stocks that work for billionaires aren't necessarily appropriate for every investor. 
Via The Motley Fool
Analyst Ratings For Axsome Therapeutics
Via Benzinga
2 Under-the-Radar Growth Stocks to Consider
Don't ignore these innovative companies. 
Via The Motley Fool
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
Don’t miss out on these three strong buy biotech stocks that are leaders to add to your portfolio for Q2 this year. 
Via InvestorPlace
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
What Analysts Are Saying About Axsome Therapeutics Stock
Via Benzinga
What Analysts Are Saying About Axsome Therapeutics Stock
Via Benzinga
Earnings Outlook For Axsome Therapeutics
Via Benzinga
The Latest Analyst Ratings For Axsome Therapeutics
Via Benzinga
What's Going On Neurology-Focused Axsome Therapeutics' Stock On Monday?
Unlock insights from the SYMPHONY Phase 3 trial of AXS-12 (reboxetine) in narcolepsy patients. AXS-12 demonstrated significant reductions in cataplexy attacks, improved daytime wakefulness, and... 
Via Benzinga
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
The price could be right for these three biopharma stocks. 
Via The Motley Fool
3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024
Find out which under-the-radar biotech stocks have major catalysts on the horizon, and unlock their explosive growth potential. 
Via InvestorPlace
3 Biotech Stocks to Buy and Hold for the Next 10 Years
There's a lot to like about these three drugmakers right now, and that shouldn't stop anytime soon. 
Via The Motley Fool
Axsome Therapeutics (AXSM) Q4 2023 Earnings Call Transcript
AXSM earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Neurology-Focused Axsome Therapeutics Reports Deeper Than Expected Q4 Loss, Updates Upcoming Pipeline Milestones
Axsome Therapeutics Q4 2023 revenues surge to $71.53 million, Auvelity sales hit $130.1 million for the year. Sunosi sees 67% YoY growth. 
Via Benzinga
The Analyst Landscape: 6 Takes On Axsome Therapeutics
Via Benzinga
Axsome Tumbles On An Unexpected Setback For Its Alzheimer's Drug
The company is testing a treatment for patients with agitation due to Alzheimer's disease. 
Via Investor's Business Daily
2 Stocks That Could Double Your Money in 5 Years
These market-beating stocks could be just getting started. 
Via The Motley Fool
UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst
UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. Positive Phase 3 data for Alzheimer's Agitation and Narcolepsy. 
Via Benzinga
Cramer Praises Asset Manager's 'Amazing Quarter,' But As For SolarEdge? 'Too Hard To Own'
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying BlackRock, Inc. (NYSE: BLK). 
Via Benzinga
Axsome Depression Drug's Commercial Success, Pipeline Potential Undervalued, Analyst Says
Axsome Therapeutics' growth potential with RBC Capital's optimistic coverage. Auvelity's rapid Rx growth projects sales of $296M in 2024, outperforming estimates. 
Via Benzinga
Earnings Scheduled For February 20, 2024
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion. 
Via Benzinga
Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating
Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
3 Stocks That Have Turned $50,000 Into More Than $500,000 in Just 5 Years
Is it too late to invest in these fast-growing stocks? 
Via The Motley Fool
2 Biotech Stocks You Can Buy and Hold for the Next Decade
The types of innovative drugs these companies develop are always in high demand. 
Via The Motley Fool
Prediction: These 3 Stocks Will Soar in 2024
Investors could enjoy an especially happy new year with these great stocks. 
Via The Motley Fool
3 Unstoppable Stocks to Buy Right Now
These stocks could be just the ticket for investors seeking strong growth. 
Via The Motley Fool
3 Biotech Stocks That Could Be Millionaire Makers
Many biotech stocks offer exciting long-term growth prospects. 
Via The Motley Fool
3 Growth Stocks to Buy Right Now Without Any Hesitation
Investors shouldn't have to deliberate for too long about these great stocks. 
Via The Motley Fool
3 Healthcare Stocks That Have More Than Doubled in Value Since the Fed Started Raising Interest Rates
Can these promising growth stocks continue rising in value? 
Via The Motley Fool
Topics Economy
Exposures Interest Rates
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.